Halberd Corporation
HALB - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$876.99K
Close$
$-0.00
112.5% downside
Current Fair Value
112.5% downsideOvervalued by 112.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $876,988.00 |
|---|---|
| Enterprise Value | $1.03 Million |
| Earnings per Share | $0 |
| Beta | 0.13 |
| Outstanding Shares | 707,303,413 |
Return
| Return on Equity | 5.09% |
|---|---|
| Return on Assets | -1079.88% |
| Return on Invested Capital | 5.56% |
Valuation & Multiples
| P/E Ratio | -27.03 |
|---|---|
| PEG | -3.84 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -25.5 |
| Enterprise Value to Net Income | -24 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | -0.17 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Halberd Corporation
3 employees
CEO: William A. Hartman
Halberd Corporation is a biotechnology firm dedicated to pioneering therapies for neurodegenerative conditions. The company's therapeutic focus encompasses a broad range of serious illnesses, including post-traumatic stress disorder (PTS...